Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Receivables (2017 - 2025)

Assembly Biosciences (ASMB) has 9 years of Change in Receivables data on record, last reported at $912000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables changed N/A year-over-year to $912000.0; the TTM value through Sep 2025 reached $869000.0, changed N/A, while the annual FY2024 figure was -$43000.0, 95.23% up from the prior year.
  • Change in Receivables reached $912000.0 in Q3 2025 per ASMB's latest filing, up from -$43000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $912000.0 in Q3 2025 and bottomed at -$1.0 million in Q1 2021.
  • Average Change in Receivables over 5 years is -$22714.3, with a median of -$22000.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: soared 118.31% in 2022, then crashed 37400.0% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$433000.0 in 2021, then surged by 30.25% to -$302000.0 in 2022, then skyrocketed by 114.24% to $43000.0 in 2023, then plummeted by 200.0% to -$43000.0 in 2024, then surged by 2220.93% to $912000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $912000.0 in Q3 2025, -$43000.0 in Q2 2024, and $43000.0 in Q4 2023.